MoneyWorks4Me

Accretion Nutraveda Ltd (544694)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544694 NSE: Pharmaceuticals & Drugs | Small Cap | Accretion Nutraveda Share Price

₹299 0.00 (0.00%)

As on 12-Aug'26 16:59

Accretion Nutraveda Ltd (544694)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544694 NSE: Pharmaceuticals & Drugs | Small Cap | Accretion Nutraveda Share Price

₹299 0.00 (0.00%)

As on 12-Aug'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹216 Cr.
Current Price
₹299
52-Week Low / High
₹150 / 304
TTM EPS
₹7
TTM Sales
₹33.6 Cr.
Book Value per Share
₹43.6
P/E Ratio
42.71
In line with its 5-year historical median
Industry PE
53.4
Price to Book (P/B)
6.86
Higher than its 5-year historical median
Price to Sales (P/S)
6.44
In line with its 5-year historical median
EV/EBITDA
30.10
In line with its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
27.68%
Outperforms industry median
Return on Capital Employed (ROCE)
30.19%
Outperforms industry median
Return on Assets (ROA)
19.38%
Operating Profit Margin
20.5%
Net Profit Margin
15.08%
Gross Profit Margin
19.3%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
110%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
85.48%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
102.8%
Asset Quality
Promoter Holding
73.48%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹28 Cr.
Equity
₹7.2 Cr.
Face Value
₹10
All Time Low / High
₹150.10 / 303.50

Accretion Nutraveda stock performance

Key Ratios
mw4me loader

Check Before You Invest

Quality

Somewhat Good

Valuation

Somewhat Overvalued

Price Trend

Weak
Q.1 Is Accretion Nutraveda Ltd a good quality company?
Accretion Nutraveda Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Accretion Nutraveda Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Accretion Nutraveda Ltd vs industry peers?
Accretion Nutraveda Ltd revenue CAGR is 126.28%, compared to the industry median CAGR of 7.81%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Accretion Nutraveda Ltd?
Promoters hold 73.48% of the Accretion Nutraveda Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Accretion Nutraveda Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Accretion Nutraveda Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Mar'23Mar'24Mar'25Mar'26TTM
ROCE % 21.4%42%57.7%30.2%-
Value Creation
Index
0.52.03.11.2-

Growth Parameters

Sales 2.951633.634
Sales YoY Gr.-72.8%219.4%110%-
Adj EPS 0.82.35.177
YoY Gr.-192.3%125%36.5%-
BVPS (₹) 0.7310.443.643.6
Adj Net
Profit
0.30.82.55.15
Cash Flow from Ops. 0.70.2-2.2-9.4-
Debt/CF from Ops. 2.99.4-1.7-0.5-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NANA126.3%110%
Adj EPS NANA107.8%36.5%
BVPSNANA290.9%320.4%
Share Price - - - -

Key Financial Parameters

Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity %
106.7121.981.52516.1
Op. Profit
Mgn %
21.424.523.320.5NAN
Net Profit
Mgn %
9.716.415.615.115.1
Debt to
Equity
7.520.80.1-
Working Cap
Days
02051351910
Cash Conv.
Cycle
058941250

Valuation of Accretion Nutraveda - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'23Mar'24Mar'25Mar'26
Sales351634
Operating Expenses + 241227
Manufacturing Costs0011
Material Costs231124
Employee Cost 0001
Other Costs 0011
Operating Profit 1147
Operating Profit Margin (%) 21.4%24.5%23.3%20.5%
Other Income + 0000
Exceptional Items 0000
Interest 0001
Depreciation 0000
Profit Before Tax 0136
Tax 0011
Profit After Tax 0135
PAT Margin (%) 9.7%16.4%15.6%15.1%
Adjusted EPS (₹)0.82.35.17.0
Dividend Payout Ratio (%)0%0%0%0%
PARTICULARSMar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 01535
Share Capital 0007
Reserves -01528
Debt +2244
Long Term Debt1124
Short Term Debt0110
Minority Interest0000
Trade Payables2111
Others Liabilities 0112
Total Liabilities 451142

Fixed Assets

Net Fixed Assets +1122
Gross Block2233
Accumulated Depreciation0111
CWIP 0000
Investments 0000
Inventories1259
Trade Receivables1038
Cash Equivalents 00010
Others Assets 01113
Total Assets 451142
PARTICULARSMar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity + 10-2-9
PBT 0136
Adjustment 1111
Changes in Working Capital -0-1-5-15
Tax Paid 0-0-1-2
Cash Flow From Investing Activity + -0-0-1-15
Capex -0-0-1-6
Net Investments 000-8
Others 0000
Cash Flow From Financing Activity + -1-0325
Net Proceeds from Shares 00225
Net Proceeds from Borrowing -1-121
Interest Paid -0-0-0-1
Dividend Paid 0000
Others 01-0-1
Net Cash Flow 00-01
PARTICULARSMar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)N/A121.9481.527.68
ROCE (%)N/A4257.6630.19
Asset Turnover Ratio0.721.152.111.28
PAT to CFO Conversion(x)N/A0-0.67-1.8
Working Capital Days
Receivable Days100.6038.3040.1061.80
Inventory Days162.8013479.5073.80
Payable Days354.90161.9030.8012.40

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Accretion Nutraveda Ltd FAQs

The current trading price of Accretion Nutraveda on 12-Aug-2026 16:59 is ₹299.0.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 11-Aug-2026 the market cap of Accretion Nutraveda stood at ₹216.5 Cr

The latest P/E ratio of Accretion Nutraveda as of 11-Aug-2026 is 42.71.

The latest P/B ratio of Accretion Nutraveda as of 11-Aug-2026 is 6.86.

The 52-week high of Accretion Nutraveda is ₹303.5 and the 52-week low is ₹150.1.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Accretion Nutraveda is ₹33.60 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Accretion Nutraveda Ltd is a average quality company.

The key valuation ratios of Accretion Nutraveda Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Accretion Nutraveda Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Accretion Nutraveda Ltd

Accretion Nutraveda was incorporated on March 16, 2021 as ‘Accretion Nutraveda Private Limited’ which further converted on May 02, 2025 as ‘Accretion Nutraveda Limited’, a public limited company. It is in the business of the manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. It is a healthcare focused company specialising in contract manufacturing, serving domestic as well as export markets in various countries. It offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science.

Its product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support. It also manufactures Capsules, including hard gelatin and HPMC capsules, targeting areas like liver detoxification, women’s health, and cognitive support. Its oral liquids include syrups, suspensions, and tonics, which are particularly suited for paediatric and geriatric segments. Additionally, it produces Traditional Ayurvedic Powders known as churans for digestive health, medicated ayurvedic oils for musculoskeletal and dermatological applications using traditional processes, and a range of external preparations like balms, ointments, creams, and gels for pain relief, skin care, and hair care.

Its leased manufacturing facility is designed for ayurvedic and nutraceutical production and is equipped with significant infrastructure that includes few Air Handling Units with HEPA filters, dedicated processing areas, and separate dispensing booths to prevent cross-contamination. The facility holds multiple certifications that attest to its adherence to quality and safety standards, including GMP certification for the manufacture of Ayurveda, Siddha & Unani Drugs from the Gujarat FDCA, WHO-GMP certification, FSSC 22000 for Food Safety Systems, ISO 9001:2015 for Quality Management Systems, ISO 45001:2018 for Occupational Health and Safety, as well as Halal certification and an FSSAI license.

Business area of the company

The company is engaged in manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, and Oral Powders, etc. It is a healthcare focused company specialising in contract manufacturing, serving domestic as well as export markets in various countries. It offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science.

Products of the company

  • Tablets
  • Capsules
  • Oral Liquids
  • Oral Powders / Churans (Oral Ayurvedic Powders)
  • Oils
  • External Preparations

Awards and recognitions

  • 2024-25: The company was awarded the ISO 9001:2015 certification, recognizing its compliance with internationally accepted standards for quality management systems, ensuring consistency in products and services with a focus on customer satisfaction and continual improvement. 
  • 2024-25: The company achieved the ISO 45001:2018 certification, demonstrating its adherence to globally recognized occupational health and safety management standards aimed at improving employee safety, reducing workplace risks, and creating a safe and healthy work environment.
  • 2024-25: The company obtained the WHO-GMP (Good Manufacturing Practices) certification from Star Certifications UK, evidencing that its manufacturing facilities and processes comply with the guidelines prescribed by the World Health Organization for ensuring product quality, safety, and efficacy. 
  • 2025-26: The company was awarded the Halal Certification from Star Certifications UK, confirming that its manufacturing processes, raw materials, and finished products conform to the requirements of the Halal Certification Scheme, thereby facilitating access to global markets that mandate Halal-compliant products.

History and milestones

  • 2020-21: The company was incorporated as a Private Limited Company.
  • 2021-22: The company entered into a lease deed for a period of 10 years.
  • 2025-26: The company was converted from a Private Limited Company into a Public Limited Company.
  • 2025-26: The company entered into a lease deed for a period of 10 years for the proposed manufacturing unit.

You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: